keynote-555: pembrolizumab bioavailability after subcutaneous administration in melanoma
Published 3 years ago • 736 plays • Length 7:19Download video MP4
Download video MP3
Similar videos
-
0:33
keynote-716: pembrolizumab in stage 2b/2c cutaneous melanoma
-
3:39
keynote-716: pembrolizumab for patients with high-risk stage ii melanoma
-
1:08
keynote-716: safety profile and results of pembrolizumab for melanoma
-
0:43
keynote-716: adjuvant pembrolizumab for high-risk melanoma
-
5:54
keynote-716: adjuvant therapy with pembrolizumab for patients with high-risk stage ii melanoma
-
1:36
results from keynote-716: adjuvant therapy with pembrolizumab in high-risk stage ii melanoma
-
4:10
a personalized mrna vaccine with pembrolizumab in melanoma
-
2:34
keynote-029: pembrolizumab with ipilimumab for melanoma
-
3:07
the keynote-001 trial: a breakthrough for pembrolizumab
-
2:31
pembrolizumab demonstrates improvement in distant metastasis-free survival in patients with melanoma
-
2:21
final analysis of keynote-585: pembrolizumab and chemotherapy in g/gej cancer
-
2:22
keynote-057: extended follow-up of pembrolizumab in bladder cancer
-
1:56
dr. levy on impact of nivolumab, pembrolizumab approvals in nsclc
-
1:12
investigators present updated results of the opacin trial for melanoma
-
1:41
sequencing of immunotherapy in melanoma
-
6:40
keynote-100 update: pembrolizumab in patients with advanced recurrent ovarian cancer
-
1:44
intratumoral immunotherapy with bo-112 pembrolizumab in patients with anti-pd1 refractory melanoma
-
2:03
antibiotics impact outcomes with pembrolizumab in nsclc patients
-
0:46
the benefits of nivolumab and relatlimab in melanoma